Avadel fell 5% in premarket trading. "Avadel is pleased with the Court’s decision allowing the commercial launch of LUMRYZ in ...

The cost of Lumryz can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Lumryz. As with all medications ...

LUMRYZ is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at ...

The company’s product, LUMRYZ, is highlighted as the first once-at-bedtime treatment for narcolepsy, which has been included in robust data supporting its use and addressing underutilization of ...

Thorpy, M.D., an investigator for the Phase 3 REST-ON trial of LUMRYZ™, Director at the Sleep-Wake Disorders Center at Montefiore Medical Center and Professor of Neurology at the Albert Einstein ...

Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21 ...

Specifically: In Q1 2025 patient demand metrics for LUMRYZ™, Avadel’s innovative narcolepsy medication with a market potential of a billion dollars in peak annual sales, all improved versus Q4 ...

Thorpy, M.D., an investigator for the Phase 3 REST-ON trial of LUMRYZ™, Director at the Sleep-Wake Disorders Center at Montefiore Medical Center and Professor of Neurology at the Albert Einstein ...

REVITALYZTM, the Company's Phase 3 pivotal trial studying LUMRYZ in Idiopathic Hypersomnia (IH), is on track to complete enrollment in the second half of 2025. Avadel has initiated four patent ...